Prescriber's Corner
Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
Alison Steinbach, PharmD, Stephen M. Clark, PharmD, and Amber B. Clemmons, PharmD, BCOP
From Georgia Regents Medical Center and University of Georgia College of Pharmacy, Augusta, Georgia
Correspondence to: Alison Steinbach, PharmD, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212.
E-mail: asteinba@wpahs.org
J Adv Pract Oncol 2013;4:451–455 |
DOI: 10.6004/jadpro.2013.4.6.8 |
© 2013 Harborside Press®
ABSTRACT
Bosutinib (Bosulif), a new second-generation tyrosine kinase inhibitor targeting the Bcr-Abl protein, was recently approved by the FDA for the treatment of select CML patients with resistance or intolerance to prior therapy. Read about the key trials, dosing and administration, and side effects of this important agent.
For access to the full length article, please
sign in.
